Document:

Exhibit 10.16

 

July 14, 2021

 

James Bloem

At the Address on File with the Company

 

		Re:	Director Transaction Bonus

 

Dear Jim:

 

In recognition of your service
as a member of the Board of Directors of Rotech Healthcare Holdings Inc. (the “Board”) in connection with its initial
public offering (“IPO”), the Board has selected you to receive a special transaction bonus in connection with the IPO
(the “Transaction Bonus”), payable in a combination of cash, stock options and restricted stock units, as set forth
below. Please read the terms of this letter carefully.

 

1.            Forms
of Payment; Vesting. Provided you continue to serve as a member of the Board through the date of the IPO (the “IPO Date”),
you will be entitled to receive the Transaction Bonus, which shall have an aggregate value of $390,000 and shall be payable in the following
forms:

 

		(ii)	a cash payment in the amount of $130,000, which shall vest and be paid to you on the IPO Date;

 

		(iii)	a stock option award granted under the Rotech Healthcare Holdings Inc. 2021 Omnibus Incentive Plan (the
 “Stock Plan”) with a grant date fair value equal to $130,000 determined as of the IPO Date and a five (5)-year term
(the “Transaction Stock Option Award”), which shall vest in equal installments on each of the 6-, 12- and 18-month
anniversaries of the IPO Date, provided you continue to serve as a member of the Board through each applicable vesting date, and

 

		(iv)	a restricted stock unit award granted under the Stock Plan with a grant date fair value equal to $130,000
determined as of the IPO Date (the “Transaction RSU Award”), which shall vest in equal installments on each of the
6-, 12- and 18-month anniversaries of the IPO Date, provided you continue to serve as a member of the Board through each applicable vesting
date.

 

2.            Treatment
on Termination. In the event your service as a member of the Board is terminated by Rotech Healthcare Holdings Inc. (the “Company”)
following the IPO Date without Cause (as defined under the Stock Plan) or due to your failure to be re-elected at an annual stockholders’
meeting, any portion of the Transaction Stock Option Award and Transaction RSU Award that is unvested as of the date of your termination
from the Board shall immediately vest in full and any vested portion of the Transaction Stock Option Award shall remain outstanding for
the remainder of its original term. In the event your service as a member of the Board is terminated due to your resignation for any reason
following the IPO Date, any portion of the Transaction Stock Option Award and Transaction RSU Award that is unvested as of the date of
your resignation shall be forfeited and cancelled for no consideration and any vested portion of the Transaction Stock Option Award shall
be treated in accordance with the terms of the Plan and the applicable award agreement. In the event your service as a member of the Board
is terminated by the Company for Cause following the IPO Date, any portion of the Transaction Stock Option Award (whether vested or unvested)
and any unvested portion of the Transaction RSU Award that remains outstanding as of the date of such termination shall be forfeited and
cancelled for no consideration.

 

    

     

    

 

3.            General
Provisions.

 

(a)           Expiration.
Notwithstanding anything herein to the contrary, unless otherwise extended by the Board, in the event the IPO Date does not occur by October 23,
2022, this letter shall terminate ab initio and shall be of no further force and your eligibility to receive the Transaction Bonus
hereunder shall be forfeited and cancelled for no consideration. For the avoidance of doubt, in the event you cease to serve as a member
of the Board through the IPO Date for any reason, this letter shall terminate ab initio and shall be of no further force and your
eligibility to receive the Transaction Bonus hereunder shall be forfeited and cancelled for no consideration.

 

(b)           Amendments
and Waivers. Any provision of this letter may be amended or waived but only if the amendment or waiver is in writing and signed, in
the case of an amendment, by you and the Company or, in the case of a waiver, by the party that would have benefited from the provision
waived.

 

(c)           Counterparts.
This letter may be executed as counterparts, each of which will constitute an original and all of which, when taken together, will constitute
one agreement.

 

(d)           Administration.
The Board will have the authority to administer and interpret this letter in its sole discretion and any determinations made by the Board
will be final, binding and conclusive.

 

(e)           Notices.
All notices, requests, demands and other communications under this letter must be in writing and addressed to (i) the Company at
its corporate headquarters and to the attention of its General Counsel and (ii) to you at the address on file with the Company from
time to time.

 

(f)            Taxes.
Any amounts payable or otherwise provided in connection with the Transaction Bonus are subject to applicable federal, state and local
taxes and tax reporting. As a non-employee director, you are responsible for the payment of all taxes related to the Transaction Bonus.

 

(g)           Governing
Law. The laws of the State of Florida, without giving effect to its conflict of laws principles, govern all matters arising out of
or relating to this letter, including its interpretation, construction, performance and enforcement.

 

*                                                     *                                                     *

 

    

     

    

 

We thank you for the service
you have rendered to the Company in the past and look forward to your continued service. Please acknowledge your acceptance of the terms
of this letter by signing below and returning a copy of this letter to me.

 

	 	Sincerely,
	 
	 	Rotech Healthcare Holdings Inc.
	 
	 	/s/ Tim Pigg
	 	Name: Tim Pigg
	 	Title: Chief Executive Officer
	 
	ACKNOWLEDGED:	 
	 
	/s/ James Bloem	 
	James Bloem	 
	 	 
	Date: July 14, 2021Exhibit 10.17

 

July 15, 2021

 

Timothy Lavelle

At the Address on File with the Company

 

		Re:	Director Transaction Bonus

 

Dear Tim:

 

In recognition of your service
as a member of the Board of Directors of Rotech Healthcare Holdings Inc. (the “Board”) in connection with its initial
public offering (“IPO”), the Board has selected you to receive a special transaction bonus in connection with the IPO
(the “Transaction Bonus”), payable in a combination of cash, stock options and restricted stock units, as set forth
below. Please read the terms of this letter carefully.

 

1.            Forms
of Payment; Vesting. Provided you continue to serve as a member of the Board through the date of the IPO (the “IPO Date”),
you will be entitled to receive the Transaction Bonus, which shall have an aggregate value of $58,500 and shall be payable in the following
forms:

 

		(ii)	a cash payment in the amount of $19,500, which shall vest and be paid to you on the IPO Date;

 

		(iii)	a stock option award granted under the Rotech Healthcare Holdings Inc. 2021 Omnibus Incentive Plan (the
 “Stock Plan”) with a grant date fair value equal to $19,500 determined as of the IPO Date and a five (5)-year term
(the “Transaction Stock Option Award”), which shall vest in equal installments on each of the 6-, 12- and 18-month
anniversaries of the IPO Date, provided you continue to serve as a member of the Board through each applicable vesting date, and

 

		(iv)	a restricted stock unit award granted under the Stock Plan with a grant date fair value equal to $19,500
determined as of the IPO Date (the “Transaction RSU Award”), which shall vest in equal installments on each of the
6-, 12- and 18-month anniversaries of the IPO Date, provided you continue to serve as a member of the Board through each applicable vesting
date.

 

2.            Treatment
on Termination. In the event your service as a member of the Board is terminated by Rotech Healthcare Holdings Inc. (the “Company”)
following the IPO Date without Cause (as defined under the Stock Plan) or due to your failure to be re-elected at an annual stockholders’
meeting, any portion of the Transaction Stock Option Award and Transaction RSU Award that is unvested as of the date of your termination
from the Board shall immediately vest in full and any vested portion of the Transaction Stock Option Award shall remain outstanding for
the remainder of its original term. In the event your service as a member of the Board is terminated due to your resignation for any reason
following the IPO Date, any portion of the Transaction Stock Option Award and Transaction RSU Award that is unvested as of the date of
your resignation shall be forfeited and cancelled for no consideration and any vested portion of the Transaction Stock Option Award shall
be treated in accordance with the terms of the Stock Plan and the applicable award agreement. In the event your service as a member of
the Board is terminated by the Company for Cause following the IPO Date, any portion of the Transaction Stock Option Award (whether vested
or unvested) and any unvested portion of the Transaction RSU Award that remains outstanding as of the date of such termination shall be
forfeited and cancelled for no consideration.

 

    

     

    

 

3.            General
Provisions.

 

(a)           Expiration.
Notwithstanding anything herein to the contrary, unless otherwise extended by the Board, in the event the IPO Date does not occur by October 23,
2022, this letter shall terminate ab initio and shall be of no further force and your eligibility to receive the Transaction Bonus
hereunder shall be forfeited and cancelled for no consideration. For the avoidance of doubt, in the event you cease to serve as a member
of the Board through the IPO Date for any reason, this letter shall terminate ab initio and shall be of no further force and your
eligibility to receive the Transaction Bonus hereunder shall be forfeited and cancelled for no consideration.

 

(b)           Amendments
and Waivers. Any provision of this letter may be amended or waived but only if the amendment or waiver is in writing and signed, in
the case of an amendment, by you and the Company or, in the case of a waiver, by the party that would have benefited from the provision
waived.

 

(c)           Counterparts.
This letter may be executed as counterparts, each of which will constitute an original and all of which, when taken together, will constitute
one agreement.

 

(d)           Administration.
The Board will have the authority to administer and interpret this letter in its sole discretion and any determinations made by the Board
will be final, binding and conclusive.

 

(e)           Notices.
All notices, requests, demands and other communications under this letter must be in writing and addressed to (i) the Company at
its corporate headquarters and to the attention of its General Counsel and (ii) to you at the address on file with the Company from
time to time.

 

(f)            Taxes.
Any amounts payable or otherwise provided in connection with the Transaction Bonus are subject to applicable federal, state and local
taxes and tax reporting. As a non-employee director, you are responsible for the payment of all taxes related to the Transaction Bonus.

 

(g)           Governing
Law. The laws of the State of Florida, without giving effect to its conflict of laws principles, govern all matters arising out of
or relating to this letter, including its interpretation, construction, performance and enforcement.

 

*                                                                    *                                                                    *

 

    

     

    

 

We thank you for the service
you have rendered to the Company in the past and look forward to your continued service. Please acknowledge your acceptance of the terms
of this letter by signing below and returning a copy of this letter to me.

 

	 	Sincerely,
	 
	 	Rotech Healthcare Holdings Inc.
	 
	 	/s/ Tim Pigg
	 	Name: Timothy Pigg
	 	Title: Chief Executive Officer
	 
	ACKNOWLEDGED:	 
	 
	/s/ Timothy Lavelle	 
	Timothy Lavelle	 
	 
	Date: July 15, 2021

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]